Abstract
Lung cancer is one of the most commonly diagnosed malignancies and it causes more than 1 million deaths each year worldwide. Small-cell lung cancer (SCLC) accounts for about 15 to 20% of all lung cancers and it is an extremely aggressive cancer, having a response rate of 60-80% with the standard first-line chemotherapy (CT). Topotecan is a topoisomerase I inhibitor currently approved for relapsed SCLC. The authors reviewed the clinical files of SCLCs patients (pts) of a single institution, the Portuguese Institute of Oncology – Porto Centre, in a five year period. The end-points were to evaluate response rates (RR), time to progression (TTP), overall survival (OS) and toxicity profile of topotecan as a second-line treatment of SCLC. > From January of 2002 to December of 2006, 146 pts were diagnosed with SCLC, 32 were submitted to second-line treatment and 23 with topotecan. The RR was 17.4%, median TTP and median survival after topotecan were 2.8 months and 6.3 months, respectively, and median OS was 17.5 months. The incidence of grade 3 and 4 adverse events was 16.6 and 2.6%, respectively. Topotecan showed clinical activity in our unselected daily patients with relapsed SCLC, with acceptable toxicity, in accordance with the published literature.
Keywords: Small-cell lung cancer, topotecan, topoisomerase I inhibitor
Current Drug Safety
Title: Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?
Volume: 5 Issue: 2
Author(s): Ana Luisa Lourenco Moreira Faria, Emilio Macias Bravo, Marta Alexandra Silva Soares Rocha, Isabel Maria Azevedo Rocha, Ana Luisa Pequeno Coelho and Antonio Manuel Ferreira Araujo
Affiliation:
Keywords: Small-cell lung cancer, topotecan, topoisomerase I inhibitor
Abstract: Lung cancer is one of the most commonly diagnosed malignancies and it causes more than 1 million deaths each year worldwide. Small-cell lung cancer (SCLC) accounts for about 15 to 20% of all lung cancers and it is an extremely aggressive cancer, having a response rate of 60-80% with the standard first-line chemotherapy (CT). Topotecan is a topoisomerase I inhibitor currently approved for relapsed SCLC. The authors reviewed the clinical files of SCLCs patients (pts) of a single institution, the Portuguese Institute of Oncology – Porto Centre, in a five year period. The end-points were to evaluate response rates (RR), time to progression (TTP), overall survival (OS) and toxicity profile of topotecan as a second-line treatment of SCLC. > From January of 2002 to December of 2006, 146 pts were diagnosed with SCLC, 32 were submitted to second-line treatment and 23 with topotecan. The RR was 17.4%, median TTP and median survival after topotecan were 2.8 months and 6.3 months, respectively, and median OS was 17.5 months. The incidence of grade 3 and 4 adverse events was 16.6 and 2.6%, respectively. Topotecan showed clinical activity in our unselected daily patients with relapsed SCLC, with acceptable toxicity, in accordance with the published literature.
Export Options
About this article
Cite this article as:
Moreira Faria Luisa Lourenco Ana, Bravo Macias Emilio, Soares Rocha Alexandra Silva Marta, Azevedo Rocha Maria Isabel, Pequeno Coelho Luisa Ana and Ferreira Araujo Manuel Antonio, Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936123
DOI https://dx.doi.org/10.2174/157488610790936123 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicity of Ionic Liquids Towards Mammalian Cell Lines
Current Organic Chemistry Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Genetics of Preneoplasia: Lessons from Lung Cancer
Current Molecular Medicine Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Cancer Chemotherapy by Novel Bio-active Natural Products: Looking Towards the Future
Current Cancer Therapy Reviews Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: Brave New World? Arrestin Pathway Bias in Drug Design (Guest Editor: Bradley T. Andresen)]
Endocrine, Metabolic & Immune Disorders - Drug Targets The Use of Conformational Restriction in Medicinal Chemistry
Current Topics in Medicinal Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach
Current Respiratory Medicine Reviews Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry